Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 10/2011

Open Access 01-10-2011 | Original Article

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Authors: Nicola Di Renzo, Antonella Montanini, Donato Mannina, Alessandra Dondi, Stefania Muci, Salvatrice Mancuso, M. Rosaria De Paolis, Caterina Plati, Caterina Stelitano, Catia Patti, Attilio Olivieri, Eliana Liardo, Gabriele Buda, Renato Cantaffa, Massimo Federico

Published in: Supportive Care in Cancer | Issue 10/2011

Login to get access

Abstract

Purpose

The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT3) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids.

Methods

Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting and no rescue therapy during overall phase (0–120 h) was the primary endpoint. Complete control (CC) defined as CR and only mild nausea was a secondary endpoint.

Results

Eighty-six evaluable patients entered in the study. A CR was observed in 74 patients (86.0%) during the overall phase; the CR during the acute (0–24 h) and delayed (24–120 h) phases was 90.7% and 88.4%, respectively. CC was 89.5% during the acute and 84.9% during the delayed phase; the overall CC was 82.6%.

Conclusions

This was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients with aggressive non-Hodgkin’s lymphoma receiving MEC regimen containing steroids.
Literature
1.
Herrstedt J (2008) Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 5(1):32–43PubMedCrossRef
2.
Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932–2947PubMedCrossRef
3.
Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20–28PubMedCrossRef
4.
Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update. Support Care Cancer 13(2):80–84PubMedCrossRef
5.
Vardy J, Chiew KS, Galica J et al (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94(7):1011–1015PubMedCrossRef
6.
Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23(6):1289–1294PubMedCrossRef
7.
Siddiqui MA, Scott LJ (2004) Palonosetron Drugs 64(10):1125–1132, discussion 1133-4CrossRef
8.
Wong EH, Clark R, Leung E et al (1995) The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 114(4):851–859PubMed
9.
Rojas C, Stathis M, Thomas AG et al (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107(2):469–478PubMedCrossRef
10.
Rojas C, Thomas AG, Alt J et al (2009) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626(2–3):193–199PubMed
11.
Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441–1449PubMedCrossRef
12.
Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473–2482PubMedCrossRef
13.
Gralla R, Lichinitser M, Van Der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570–1577PubMedCrossRef
14.
Rubenstein E, Gralla R, Eisenberg P, et al (2003) Palonosetron (PALO) compared with ondansetron (OND) or dolasetron (DOL) for prevetion of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Combined results of two phase III trials. In: Proc Am Soc Clin Oncol 22: (abstr 2932)
15.
Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124PubMedCrossRef
16.
Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103–109PubMed
17.
Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38(1):143–151PubMedCrossRef
18.
19.
Sharma R, Tobin P, Clarke SJ (2005) Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6(2):93–102PubMedCrossRef
20.
Herrstedt J, Aapro MS, Smyth JF et al (1998) Corticosteroids, dopamine antagonists and other drugs. Support Care Cancer 6(3):204–214PubMedCrossRef
21.
Allan SG, Cornbleet MA, Warrington PS et al (1984) Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. Br Med J (Clin Res Ed) 289(6449):878–879CrossRef
22.
The Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332(1):1–5CrossRef
23.
Roila F, Tonato M, Cognetti F et al (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9(4):675–678PubMed
24.
Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Grou. J Clin Oncol 21(22):4112–4119PubMedCrossRef
25.
Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822–2830PubMedCrossRef
26.
Giuliani F, Cilenti G, Nugnes I, et al (2008) Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant FOLFOX-4 regimen in colorectal cancer (CRC) patients: a phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). In: Eur J Cancer Supplements
27.
Aapro MS (2007) Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag 3(6):1009–1020PubMed
28.
Jorgensen M, Victor MA (1996) Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy. Acta Oncol 35(2):159–163PubMedCrossRef
29.
Numbenjapon T, Sriswasdi C, Mongkonsritragoon W et al (2002) Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma. J Med Assoc Thai 85(11):1156–1163PubMed
30.
Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242PubMedCrossRef
31.
Aapro M, Fabi A, Nole F et al (2010) Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol 21(5):1083–1088PubMedCrossRef
32.
Celio L, Frustaci S, Denaro A, et al (2010) Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer
Metadata
Title
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
Authors
Nicola Di Renzo
Antonella Montanini
Donato Mannina
Alessandra Dondi
Stefania Muci
Salvatrice Mancuso
M. Rosaria De Paolis
Caterina Plati
Caterina Stelitano
Catia Patti
Attilio Olivieri
Eliana Liardo
Gabriele Buda
Renato Cantaffa
Massimo Federico
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 10/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0974-y

Other articles of this Issue 10/2011

Supportive Care in Cancer 10/2011 Go to the issue

Original Article

Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis

Letter to the Editor

Inaccuracy in the article “Managing chronic pain: results from an open-label study using MC5-A Calmare® device in Support Care Cancer”

Original Article

Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)

Original Article

Factors predicting clinically significant fatigue in women following treatment for primary breast cancer

Original Article

Cancer patients’ informational needs on health promotion and related factors: a multi-institutional, cross-sectional study in Korea

Original Article

Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits